Announcements Trials
Browse Landscape

Status

Recruiting 1

Sponsor Class

OTHER_GOV 1

Study Type

Observational 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1Gastrointestinal 1

Conditions

Kidney Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1

Interventions

pembrolizumab 14Nivolumab 6Carboplatin 5sargramostim 4Fluorouracil 4Drug Therapy 4Thiotepa 3Sorafenib 3Radiotherapy 3Ipilimumab 3Interferon-alpha 3Gemcitabine 3Filgrastim 3Counseling 3Cetuximab 3liposomal doxorubicin 2ixabepilone 2entinostat 2cemiplimab 2belinostat 2atezolizumab 2Temozolomide 2Surveys and Questionnaires 2Sirolimus 2Psychiatric Rehabilitation 2Polymerase Chain Reaction 2Paclitaxel 2Methods 2Melphalan 2Irinotecan 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Kidney Neoplasms × Blood Cell Count × Gastrointestinal × Clear all
NCT07485114 2026-03-20

Association Between Galectin-3 Levels and Outcomes in Patients With Renal Cell Carcinoma, Transitional Cell Carcinoma , Non Small Cell Lung Cancer, and Hepatocellular Carcinoma, Treated With PD-1/PDL-1 Inhibitors

Tel-Aviv Sourasky Medical Center

Recruiting
300 enrolled
GastrointestinalGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinoma, Hepatocellular, Kidney Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡